A citation-based method for searching scientific literature

Xiao-Dong Zheng, Qiang Qu, Xing-Yu Jiang, Zhong-Yuan Wang, Cheng Tang, Jin-Yu Sun. Am J Cardiovasc Drugs 2021
Times Cited: 2







List of co-cited articles
13 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
100

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
560
100

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Martina Brueckmann, Anne Pernille Ofstad, Egon Pfarr, Waheed Jamal,[...]. Lancet 2020
251
100

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Mark C Petrie, Subodh Verma, Kieran F Docherty, Silvio E Inzucchi, Inder Anand, Jan Belohlávek, Michael Böhm, Chern-En Chiang, Vijay K Chopra, Rudolf A de Boer,[...]. JAMA 2020
127
100

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Mikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, Mirta Diez, Mark C Petrie, Subodh Verma, Jose C Nicolau, Béla Merkely, Masafumi Kitakaze, David L DeMets,[...]. Circulation 2020
102
100

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
100


Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
David D Berg, Pardeep S Jhund, Kieran F Docherty, Sabina A Murphy, Subodh Verma, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez,[...]. JAMA Cardiol 2021
21
100

Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial.
Jawad H Butt, Jose C Nicolau, Subodh Verma, Kieran F Docherty, Mark C Petrie, Silvio E Inzucchi, Morten Schou, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez,[...]. Eur J Heart Fail 2021
8
100

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
Scott D Solomon, Pardeep S Jhund, Brian L Claggett, Pooja Dewan, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Silvio E Inzucchi,[...]. JACC Heart Fail 2020
32
100

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Michael E Nassif, Sheryl L Windsor, Fengming Tang, Yevgeniy Khariton, Mansoor Husain, Silvio E Inzucchi, Darren K McGuire, Bertram Pitt, Benjamin M Scirica, Bethany Austin,[...]. Circulation 2019
137
100

Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.
Li Shen, Søren Lund Kristensen, Olof Bengtsson, Michael Böhm, Rudolf A de Boer, Kieran F Docherty, Silvio E Inzucchi, Tzvetana Katova, Lars Køber, Mikhail N Kosiborod,[...]. JACC Heart Fail 2021
12
100


Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection.
Yi-Chou Hou, Cai-Mei Zheng, Tzung-Hai Yen, Kuo-Cheng Lu. Int J Mol Sci 2020
6
50

Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure.
Raktim K Ghosh, Gopal Chandra Ghosh, Manasvi Gupta, Dhrubajyoti Bandyopadhyay, Tauseef Akhtar, Prakash Deedwania, Carl J Lavie, Gregg C Fonarow, Ashish Aneja. Am J Cardiol 2019
15
50


Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
Jagdeep S S Singh, Ify R Mordi, Keeran Vickneson, Amir Fathi, Peter T Donnan, Mohapradeep Mohan, Anna Maria J Choy, Stephen Gandy, Jacob George, Faisel Khan,[...]. Diabetes Care 2020
36
50

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
Fumitaka Soga, Hidekazu Tanaka, Kazuhiro Tatsumi, Yasuhide Mochizuki, Hiroyuki Sano, Hiromi Toki, Kensuke Matsumoto, Junya Shite, Hideyuki Takaoka, Tomofumi Doi,[...]. Cardiovasc Diabetol 2018
82
50

Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?
Sérgio Maltês, Gonçalo J L Cunha, Bruno M L Rocha, João Presume, Renato Guerreiro, Célia Henriques, Catarina Rodrigues, Inês Araújo, Cândida Fonseca. Cardiology 2021
2
50

European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Petar M Seferović, Andrew J S Coats, Piotr Ponikowski, Gerasimos Filippatos, Martin Huelsmann, Pardeep S Jhund, Marija M Polovina, Michel Komajda, Jelena Seferović, Ibrahim Sari,[...]. Eur J Heart Fail 2020
63
50

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.
Sandeep R Das, Brendan M Everett, Kim K Birtcher, Jenifer M Brown, James L Januzzi, Rita R Kalyani, Mikhail Kosiborod, Melissa Magwire, Pamela B Morris, Joshua J Neumiller,[...]. J Am Coll Cardiol 2020
76
50


Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
732
50

Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA-HFpEF trial.
Mariëlle Scheffer, Annet Driessen-Waaijer, Nazha Hamdani, Jochem W D Landzaat, Nini H Jonkman, Walter J Paulus, Loek van Heerebeek. ESC Heart Fail 2020
6
50


Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
736
50

The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial.
Phil McEwan, Angharad R Morgan, Rebecca Boyce, Klas Bergenheim, Ingrid A M Gause-Nilsson, Deepak L Bhatt, Lawrence A Leiter, Peter A Johansson, Ofri Mosenzon, Avivit Cahn,[...]. Diabetes Obes Metab 2021
4
50

Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.
Chi Young Shim, Jiwon Seo, Iksung Cho, Chan Joo Lee, In-Jeong Cho, Purevjargal Lhagvasuren, Seok-Min Kang, Jong-Won Ha, Gyoonhee Han, Yangsoo Jang,[...]. Circulation 2021
14
50

Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes.
Kevin S Shah, Haolin Xu, Roland A Matsouaka, Deepak L Bhatt, Paul A Heidenreich, Adrian F Hernandez, Adam D Devore, Clyde W Yancy, Gregg C Fonarow. J Am Coll Cardiol 2017
292
50

Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.
Salim S Virani, Alvaro Alonso, Emelia J Benjamin, Marcio S Bittencourt, Clifton W Callaway, April P Carson, Alanna M Chamberlain, Alexander R Chang, Susan Cheng, Francesca N Delling,[...]. Circulation 2020
50

Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
Stephen J Greene, Javed Butler, Nancy M Albert, Adam D DeVore, Puza P Sharma, Carol I Duffy, C Larry Hill, Kevin McCague, Xiaojuan Mi, J Herbert Patterson,[...]. J Am Coll Cardiol 2018
302
50

Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure.
Petar M Seferović, Gabriele Fragasso, Mark Petrie, Wilfried Mullens, Roberto Ferrari, Thomas Thum, Johann Bauersachs, Stefan D Anker, Robin Ray, Yuksel Çavuşoğlu,[...]. Eur J Heart Fail 2020
34
50

Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis.
Diego Chambergo-Michilot, Astrid Tauma-Arrué, Silvana Loli-Guevara. Int J Cardiol Heart Vasc 2020
7
50

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel,[...]. Diabetologia 2018
202
50


Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective.
Feby Savira, Bing H Wang, Andrew R Kompa, Zanfina Ademi, Alice J Owen, Sophia Zoungas, Andrew Tonkin, Danny Liew, Ella Zomer. Eur J Prev Cardiol 2020
11
50

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.
Alexander J M Brown, Stephen Gandy, Rory McCrimmon, John Graeme Houston, Allan D Struthers, Chim C Lang. Eur Heart J 2020
38
50


Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
John J V McMurray, David C Wheeler, Bergur V Stefánsson, Niels Jongs, Douwe Postmus, Ricardo Correa-Rotter, Glenn M Chertow, Fan Fan Hou, Peter Rossing, C David Sjöström,[...]. JACC Heart Fail 2021
1
100

Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology.
Giuseppe M C Rosano, Brenda Moura, Marco Metra, Michael Böhm, Johann Bauersachs, Tuvia Ben Gal, Stamatis Adamopoulos, Magdy Abdelhamid, Vasiliki Bistola, Jelena Čelutkienė,[...]. Eur J Heart Fail 2021
7
50

Neurohormonal Blockade in Heart Failure.
Thomas G von Lueder, Dipak Kotecha, Dan Atar, Ingrid Hopper. Card Fail Rev 2017
23
50

Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
Jawad H Butt, Kieran F Docherty, Mark C Petrie, Morten Schou, Mikhail N Kosiborod, Eileen O'Meara, Tzvetana Katova, Charlotta E A Ljungman, Mirta Diez, Modele O Ogunniyi,[...]. JAMA Cardiol 2021
4
50

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.
Kieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, David L DeMets, Marc S Sabatine, Olof Bengtsson,[...]. Eur Heart J 2020
69
50


Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
233
50


The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
Filipe Ferrari, Vítor M Martins, Rafael S Scheffel, Anderson D da Silveira, Marcelo Trotte Motta, Emilio H Moriguchi, Raul D Santos, Ricardo Stein. Ann Pharmacother 2021
3
50

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.
James P Curtain, Kieran F Docherty, Pardeep S Jhund, Mark C Petrie, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine,[...]. Eur Heart J 2021
7
50

Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
Phil McEwan, Oliver Darlington, John J V McMurray, Pardeep S Jhund, Kieran F Docherty, Michael Böhm, Mark C Petrie, Klas Bergenheim, Lei Qin. Eur J Heart Fail 2020
32
50

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.
Kieran F Docherty, Pardeep S Jhund, Inder Anand, Olof Bengtsson, Michael Böhm, Rudolf A de Boer, David L DeMets, Akshay S Desai, Jaroslaw Drozdz, Jonathan Howlett,[...]. Circulation 2020
18
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.